Skip to main content
Fig. 1 | BMC Biology

Fig. 1

From: DDX39B interacts with the pattern recognition receptor pathway to inhibit NF-κB and sensitize to alkylating chemotherapy

Fig. 1

DDX39B inhibits NF-κB activity. a Luciferase assay using a reporter bearing -1C κB-sites in A172 cells expressing two independent sh-DDX39B constructs or a control vector. Data show mean value normalized to EV, ± SEM from two independent experiments. b Luciferase assay in U87 cells transfected with empty vector (EV) or DDX39B. Data show mean value normalized to EV, ± SEM from two independent experiments. c Immunoblot (IB) in A172 GBM cells expressing two sh-DDX39B constructs or sh-control. IB was performed with anti-phospho-IκBα, anti-IκBα, or anti-GAPDH as loading control. d IB in GBM34 and GBM44 GSCs probed with anti-DDX39B. e Immunoblot in GBM44 GSCs expressing shRNA constructs as in c. IB performed as in c. f Representative immunofluorescence (IF) analysis of endogenous p65 in A172 cells expressing sh-DDX39B. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI). Scale bar, 10 μm. g IB in GBM44 GSCs from e expressing shRNA constructs probed with anti-phospho-p65 and anti-p65 antibodies. h IB in GBM34 GSCs stably expressing empty vector (EV) or S-tagged DDX39B with anti-phospho-p65 and anti-p65. *P < 0.05, **P < 0.01 (two-tailed t test)

Back to article page